-
1دورية أكاديمية
المؤلفون: Facon, Thierry, Dimopoulos, Meletios A, Dispenzieri, Angela, Catalano, John V, Belch, Andrew, Cavo, Michele, Pinto, Antonello, Weisel, Katja, Ludwig, Heinz, Bahlis, Nizar J, Banos, Anne, Tiab, Mourad, Delforge, Michel, Cavenagh, Jamie D, Geraldes, Catarina, Lee, Je-Jung, Chen, Christine, Oriol, Albert, De La Rubia, Javier, White, Darell, Binder, Daniel, Lu, Jin, Anderson, Kenneth C, Moreau, Philippe, Attal, Michel, Perrot, Aurore, Arnulf, Bertrand, Qiu, Lugui, Roussel, Murielle, Boyle, Eileen, Manier, Salomon, Mohty, Mohamad, Avet-Loiseau, Herve, Leleu, Xavier, Ervin-Haynes, Annette, Chen, Guang, Houck, Vanessa, Benboubker, Lotfi, Hulin, Cyrille
المساهمون: Facon, Thierry, Dimopoulos, Meletios A, Dispenzieri, Angela, Catalano, John V, Belch, Andrew, Cavo, Michele, Pinto, Antonello, Weisel, Katja, Ludwig, Heinz, Bahlis, Nizar J, Banos, Anne, Tiab, Mourad, Delforge, Michel, Cavenagh, Jamie D, Geraldes, Catarina, Lee, Je-Jung, Chen, Christine, Oriol, Albert, De La Rubia, Javier, White, Darell, Binder, Daniel, Jin, Lu, Anderson, Kenneth C, Moreau, Philippe, Attal, Michel, Perrot, Aurore, Arnulf, Bertrand, Qiu, Lugui, Roussel, Murielle, Boyle, Eileen, Manier, Salomon, Mohty, Mohamad, Avet-Loiseau, Herve, Leleu, Xavier, Ervin-Haynes, Annette, Chen, Guang, Houck, Vanessa, Benboubker, Lotfi, Hulin, Cyrille
مصطلحات موضوعية: newly diagnosed multiple myeloma
الوصف: This FIRST trial final analysis examined survival outcomes in patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM) treated with lenalidomide and low-dose dexamethasone until disease progression (Rd continuous), Rd for 72 weeks (18 cycles; Rd18), or melphalan, prednisone, and thalidomide (MPT; 72 weeks). The primary endpoint was progression-free survival (PFS; primary comparison: Rd continuous vs MPT). Overall survival (OS) was a key secondary endpoint (final analysis prespecified ≥ 60 months' follow-up). Patients were randomized to Rd continuous (n = 535), Rd18 (n = 541), or MPT (n = 547). At a median follow-up of 67 months, PFS was significantly longer with Rd continuous vs MPT (HR, 0.69; 95% CI, 0.59-0.79; P < .00001) and was similarly extended vs Rd18. Median OS was 10 months longer with Rd continuous vs MPT (59.1 vs 49.1 months; HR, 0.78; 95% CI, 0.67-0.92; P = .0023), and similar with Rd18 (62.3 months). In patients achieving complete or very good partial responses, Rd continuous had a ≈ 30-month-longer median time to next treatment vs Rd18 (69.5 vs 39.9 months). Over half of all patients who received second-line treatment were given a bortezomib-based therapy. Second-line outcomes were improved in patients receiving bortezomib after Rd continuous and Rd18 vs after MPT. No new safety concerns, including risk for secondary malignancies, were observed. Treatment with Rd continuous significantly improved survival outcomes vs MPT, supporting Rd continuous as a standard of care for patients with transplant-ineligible NDMM. Study registration is at Clinicaltrials.gov (NCT00689936) and EudraCT (2007-004823-39).
وصف الملف: ELETTRONICO
العلاقة: info:eu-repo/semantics/altIdentifier/pmid/29150421; info:eu-repo/semantics/altIdentifier/wos/WOS:000423449900007; volume:131; issue:3; firstpage:301; lastpage:310; numberofpages:10; journal:BLOOD; http://hdl.handle.net/11585/614581Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85040837714; http://www.bloodjournal.org/content/131/3/301?sso-checked=trueTest
الإتاحة: https://doi.org/10.1182/blood-2017-07-795047Test
http://hdl.handle.net/11585/614581Test
http://www.bloodjournal.org/content/131/3/301?sso-checked=trueTest -
2دورية أكاديمية
المؤلفون: Benboubker, Lotfi, Dimopoulos, Meletios A., Dispenzieri, Angela, Catalano, John, Belch, Andrew R., Pinto, Antonello, Weisel, Katja, Ludwig, Heinz, Bahlis, Nizar, Banos, Anne, Tiab, Mourad, Delforge, Michel, Cavenagh, Jamie, Geraldes, Catarina, Lee, Je Jung, Chen, Christine, Oriol, Albert, De La Rubia, Javier, Qiu, Lugui, White, Darrell J., Binder, Daniel, Anderson, Kenneth, Fermand, Jean Paul, Moreau, Philippe, Attal, Michel, Knight, Robert, Chen, Guang, Van Oostendorp, Jason, Jacques, Christian, Ervin Haynes, Annette, Avet Loiseau, Hervé, Hulin, Cyrille, Facon, Thierry, CAVO, MICHELE
المساهمون: Benboubker, Lotfi, Dimopoulos, Meletios A., Dispenzieri, Angela, Catalano, John, Belch, Andrew R., Cavo, Michele, Pinto, Antonello, Weisel, Katja, Ludwig, Heinz, Bahlis, Nizar, Banos, Anne, Tiab, Mourad, Delforge, Michel, Cavenagh, Jamie, Geraldes, Catarina, Lee, Je-Jung, Chen, Christine, Oriol, Albert, De La Rubia, Javier, Qiu, Lugui, White, Darrell J., Binder, Daniel, Anderson, Kenneth, Fermand, Jean-Paul, Moreau, Philippe, Attal, Michel, Knight, Robert, Chen, Guang, Van Oostendorp, Jason, Jacques, Christian, Ervin-Haynes, Annette, Avet-Loiseau, Hervé, Hulin, Cyrille, Facon, Thierry
مصطلحات موضوعية: Adult, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocol, Dexamethasone, Disease-Free Survival, Female, Human, Kaplan-Meier Estimate, Male, Melphalan, Middle Aged, Multiple Myeloma, Prednisone, Thalidomide, Medicine (all)
الوصف: BACKGROUND: The combination melphalan-prednisone-thalidomide (MPT) is considered a standard therapy for patients with myeloma who are ineligible for stem-cell transplantation. However, emerging data on the use of lenalidomide and low-dose dexamethasone warrant a prospective comparison of the two approaches. METHODS: We randomly assigned 1623 patients to lenalidomide and dexamethasone in 28-day cycles until disease progression (535 patients), to the same combination for 72 weeks (18 cycles; 541 patients), or to MPT for 72 weeks (547 patients). The primary end point was progression-free survival with continuous lenalidomide-dexamethasone versus MPT. RESULTS: The median progression-free survival was 25.5 months with continuous lenalidomide-dexamethasone, 20.7 months with 18 cycles of lenalidomide-dexamethasone, and 21.2 months with MPT (hazard ratio for the risk of progression or death, 0.72 for continuous lenalidomide-dexamethasone vs. MPT and 0.70 for continuous lenalidomide-dexamethasone vs. 18 cycles of lenalidomide-dexamethasone; P<0.001 for both comparisons). Continuous lenalidomide-dexamethasone was superior to MPT for all secondary efficacy end points, including overall survival (at the interim analysis). Overall survival at 4 years was 59% with continuous lenalidomide-dexamethasone, 56% with 18 cycles of lenalidomide-dexamethasone, and 51% with MPT. Grade 3 or 4 adverse events were somewhat less frequent with continuous lenalidomide-dexamethasone than with MPT (70% vs. 78%). As compared with MPT, continuous lenalidomide-dexamethasone was associated with fewer hematologic and neurologic toxic events, a moderate increase in infections, and fewer second primary hematologic cancers. CONCLUSIONS: As compared with MPT, continuous lenalidomide-dexamethasone given until disease progression was associated with a significant improvement in progression-free survival, with an overall survival benefit at the interim analysis, among patients with newly diagnosed multiple myeloma who were ineligible for stem-cell ...
وصف الملف: STAMPA
العلاقة: info:eu-repo/semantics/altIdentifier/pmid/25184863; info:eu-repo/semantics/altIdentifier/wos/WOS:000341390600008; volume:371; issue:10; firstpage:906; lastpage:917; numberofpages:12; journal:NEW ENGLAND JOURNAL OF MEDICINE; http://hdl.handle.net/11585/528745Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-84907012637
